Nrx pharmaceuticals secures ind for urinary tract infection treatment

New york, december 19, 2023 – nrx pharmaceuticals, inc. (nasdaq: nrxp) has been granted fda clearance for its investigational new drug application (ind) for nrx-101 for the treatment of complicated urinary tract infections (cuti). the company's shares surged 25% in trading on monday following the news.

NRXP Ratings Summary

NRXP Quant Ranking